Karyopharm plans to submit an August 2026 supplemental New Drug Application seeking accelerated approval of selinexor plus ruxolitinib for JAK-inhibitor-naive myelofibrosis and intends to request Priority Review. The company reports written FDA feedback that…
Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront plus up to $1.3 billion in regulatory and commercial milestones, creating a total potential transaction value of $1.75 billion. The acquisition gives Ipsen control…
Karyopharm delivered one of the most important myelofibrosis datasets of 2026. In the Phase 3 SENTRY study, selinexor plus ruxolitinib nearly doubled spleen response rates versus ruxolitinib alone (49.8% vs 28.0%) and generated an…
Karyopharm announced an investor conference call following the June 2, 2026 ASCO oral presentation of full Phase 3 SENTRY trial results evaluating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.
